1088. Evaluating the Effect of Donepezil on Mortality Among Alzheimer’s Disease Patients With and Without COVID-19 Infection

BACKGROUND: Dementia has been identified as an independent risk factor for increased severity of COVID-19 infection. Donepezil, a cholinesterase inhibitor approved for Alzheimer’s disease (AD), has anti-inflammatory properties. Previous studies have found that donepezil reduced all-cause mortality f...

Descripción completa

Detalles Bibliográficos
Autores principales: Bej, Taissa A, Edmiston, Elizabeth, Wilson, Brigid, Phillips, Joy, Jump, Robin L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9751820/
http://dx.doi.org/10.1093/ofid/ofac492.928

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9751820/
http://dx.doi.org/10.1093/ofid/ofac492.928

Ejemplares similares